Brexpiprazole is not yet approved to treat bipolar disorder. Brexpiprazole: another multipurpose antipsychotic drug? Primary aim will be to assess if brexpiprazole is associated with a reduction in depressive symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS). by quietgirl2538 » Thu Feb 16, 2017 4:35 pm . No studies have examined brexpiprazole for bipolar depression. 2019 Oct;20(15):1907-1916. doi: 10.1080/14656566.2019.1638913. ... Manic symptoms were measured using Young Mania Rating Scale, quality of life with the Quality of Life in Bipolar Disorder (QOLBD), and cognition with Rey Auditory Verbal Learning Test, Stroop Color Word Test, and Trail Making Test. Published by Elsevier B.V. About the Studies The two trials were multicenter, randomized, double-blind, placebo-controlled phase III studies that enrolled a total of approximately 650 participants. 28-07-2017 Elsevier Science 2011 Oct 28;11:171. doi: 10.1186/1471-244X-11-171.Expert Opin Pharmacother. MADRS and IDS-SR 30 scores decreased from baseline at weeks 4 and 8. Howland R.H. Brexpiprazole: another multipurpose antipsychotic drug? Unable to load your collection due to an error 23-03-2017. eCollection 2020.J Affect Disord. Results. 2019 Oct;79(15):1657-1677. doi: 10.1007/s40265-019-01189-8. 2020 Jan;34(1):29-46. doi: 10.1007/s40263-019-00688-2.Drugs. Article Health Canada approves Rexulti. Anybody tried Rexulti (brexpiprazole)? 2015 Apr;53(4):23-5. doi: 10.3928/02793695-20150323-01. Background: Past studies suggest that brexpiprazole is an effective adjunctive treatment for major depressive disorder and schizophrenia; however, no studies have examined brexpiprazole for bipolar depression. J Clin Psychiatry. A role for serotonin 5-HT1A and 5-HT2A receptors. J Psychosoc Nurs Ment Health Serv. 2018 Apr;34(4):633-642. doi: 10.1080/03007995.2018.1430220. 2016 Dec;77(12):1695-1701. doi: 10.4088/JCP.15m10470.Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, Brewer C, Sanchez R, McQuade RD.Curr Med Res Opin. Eur Neuropsychopharmacol. This website uses cookies to improve your experience. I understand it's fairly new. COVID-19 is an emerging, rapidly evolving situation. This site needs JavaScript to work properly. In this study, we examined the effects of brexpiprazole on mood, cognition, and quality of life in outpatients with bipolar depression. Continue if you are OK with this.Danish CNS specialist Lundbeck saw its shares drop as much as 4% to 275.60 kroner today, after it released…Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our £10 per month Access The Pharma Letter's latest news free for 7 daysPLUS... you can receive the Pharma Letter headlines and news roundup email free foreverUnlimited access to The Pharma Letter site for a whole yearFor editorial enquiries, press releases and events please email The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Article US nod for injectable bipolar drug a welcome boost for Lundbeck. The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state. Elsevier Science Copyright © 2019. Has anyone tried it or heard reviews about it? Name must be less than 100 characters 2017 Feb;37(1):46-53. doi: 10.1097/JCP.0000000000000622.Neuropsychiatr Dis Treat. 2020 Jul 1;272:355-362. doi: 10.1016/j.jad.2020.03.179. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. The results from the bipolar 1 disorder mania studies do not have any bearing on the approved indications of brexpiprazole as treatment for people living with major depressive disorder (MDD) and schizophrenia. Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator. 2020 Jun 9;16:1459-1472. doi: 10.2147/NDT.S245166. J Psychosoc Nurs Ment Health Serv, 2015, 53(4), 23-5 Pubmed ; Ishima T. et al. 19-02-2017. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Epub 2019 Jul 10.Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, Han C.J Clin Psychopharmacol. Epub 2018 Jan 25.Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L.BMC Psychiatry. I am going to try this drug once I have weaned off the Abilify. Epub 2020 Apr 29.CNS Drugs. Article Brexpiprazole filed with EMA for adult patients with schizophrenia. Unable to load your delegates due to an error